Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome

ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session...
April 25, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population Patients...
April 11, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in LEERINK Partners CNS Day

EMERYVILLE, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
March 06, 2018 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDALast patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504Initiated global...
February 27, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6

EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
February 08, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference

EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
February 06, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
January 31, 2018 16:05 ET | Source: Zogenix, Inc.

Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome

Study 1504 Top-Line Data on Track for 2Q 2018 EMERYVILLE, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of...
December 04, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo Parents/Caregivers and Investigators Rated Patients Treated with ZX008 as Very...
November 29, 2017 08:05 ET | Source: Zogenix, Inc.

Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome

EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right